Latest Conference Articles

The Top 5 Conference Articles of 2022

Skylar Jeremias

December 30 2022

Conferences throughout 2022 shared new information on white bagging, the safety of biosimilar substitution, the use of a biobetter, and discussion around the role that pharmacy benefit managers play in biosimilar adoption.

AAO Posters Investigate Ranibizumab Biosimilar Impact on Patient Outcomes

Skylar Jeremias

November 2 2022

Two studies presented at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, Illinois, demonstrated the impact that a ranibizumab biosimilar (SB11; Byooviz) can have on patient outcomes.

Policy Harmonization, Clarification Could Aid Biosimilar Uptake Efforts

Skylar Jeremias

September 23 2022

Realigning definitions and policies across regulatory agencies and developing a better understanding of how different stakeholders approach biosimilars could help get more patients and providers on board with using biosimilars, according to panelists at the DIA Biosimilars Conference.

Better Patient Notification Is Needed to Improve Biosimilar Adoption

Skylar Jeremias

September 21 2022

Panelists at the DIA Biosimilars Conference discussed how biosimilars can help address health care disparities and why patient notification for switching to biosimilars must be handled with caution.

Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma

Skylar Jeremias

July 14 2022

Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.

EHA Abstracts Preview Potential for Eculizumab Contenders

Skylar Jeremias

June 21 2022

Abstracts from the 2022 European Hematology Association (EHA) Congress presented positive data for 2 biosimilar candidates referencing Soliris (eculizumab).

ASCO Studies Assess Biosimilar Substitution, Adoption in Oncology Practices

Skylar Jeremias

June 16 2022

Abstracts from the American Society of Clinical Oncology (ASCO) annual meeting took a look at the impact biosimilar substitution and increased biosimilar adoption had on spending within practices participating in value-based payment models and the Oncology Care Model.

EULAR Data Show Similarity of Samsung Bioepis Adalimumab Biosimilar to Humira

Skylar Jeremias

June 9 2022

Data showing the clinical outcomes of Samsung Bioepis’ biosimilar referencing Humira (adalimumab) were shared at the European Congress of Rheumatology’s annual meeting, EULAR 2022.

Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars

Skylar Jeremias

June 5 2022

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.

Celltrion’s Infliximab Biobetter Shows Significant Clinical Improvements Over Original Biosimilar Version

Skylar Jeremias

June 4 2022

Results from the European Congress of Rheumatology’s annual meeting revealed that Celltrion’s Remsima SC, a subcutaneous biobetter infliximab product, produced better clinical outcomes compared with the original Remsima, an infliximab biosimilar delivered intravenously.